article thumbnail

Evotec and Pfizer collaborate on metabolic and infectious diseases

Drug Discovery World

Evotec and Pfizer have entered into a multi-year research collaboration, initially focused on early discovery research for metabolic and infectious diseases. Diana Spencer, Senior Digital Content Editor, DDW The post Evotec and Pfizer collaborate on metabolic and infectious diseases appeared first on Drug Discovery World (DDW).

Disease 264
article thumbnail

Two rare disease therapies approved in Scotland

Drug Discovery World

The Scottish Medicines Consortium (SMC) has published final advice on two rare disease therapies. Elfabrio (pegunigalsidase alfa), a novel enzyme replacement therapy (ERT), has been approved as a treatment option for Fabry disease in adults. Birch bark extract gel EB is the name for a group of rare, genetic skin disorders.

Therapies 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Researchers discover genetic cause of inflammatory bowel diseases

Drug Discovery World

Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs. About 5% of the world’s population are currently affected by an autoimmune disease, such as IBD, the umbrella term for Crohn’s disease and ulcerative colitis.

Disease 147
article thumbnail

Gene therapy for Parkinson’s disease progresses to Phase II

Drug Discovery World

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and Europe.

Therapies 147
article thumbnail

Exendin?4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease

Chemical Biology and Drug Design

The figure depicts the neuroprotective role of exendin-4 in Alzheimer's disease and Parkinson's disease. Exendin-4's diverse therapeutic targets suggest its potential therapeutic uses in neurodegenerative ailments like Alzheimer's disease and Parkinson's disease and have garnered an increasing amount of attention.

Disease 189
article thumbnail

Potential disease-modifying therapy for Parkinson’s disease

Drug Discovery World

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. Parkinson’s disease is highly associated with mitochondrial dysfunction. Mission is planning to initiate a MTX325 Phase I trial in humans in early 2024.

Disease 130
article thumbnail

Case Study: Consistent assays for neurological disease drug development

Drug Discovery World

A new Case Study is now available to download for free entitled ‘ Improving physiological relevance in neurological disease drug development. Download ‘ Improving physiological relevance in neurological disease drug development.